About XOMA Royalty
XOMA Royalty is a Healthcare company based in San Diego (United States) founded in 2015 by John Bell, David Stojdl, and Brain Lichty, and was acquired by XOMA Corporation in June 2025. XOMA Royalty is engaged in biotech royalty aggregation activities. It operates on a Commission-Based model. XOMA Royalty has raised $172.06 million across 4 funding rounds from investors including Takeda Pharmaceuticals, Northleaf and Citadel. The company has 80 employees. XOMA Royalty has completed 1 acquisition, including Myst Therapeutics. Its chief executive, as recorded, is Sammy Farah. XOMA Royalty offers products and services including Royalty Acquisition and Royalty Portfolio. Its focus areas include Biotechnology and Royalty Aggregation. Its legal entity is XOMA Royalty Corporation. Its competitors include Moderna, BridgeBio and BeiGene; 3 of its 3 listed competitors have raised funding.
Company details
XOMA Royalty is involved in the aggregation of biotech royalties by acquiring economic rights to future milestone and royalty payments from pre-commercial clinical candidates. The company supports biotech firms with non-dilutive funding to advance drug development. An expansive portfolio of licenses is maintained, covering potential royalty and milestone payments for drug candidates developed by external partners. Operations are focused on mitigating single-asset risks through a diversified portfolio approach within the healthcare and biotechnology sectors.
- Headquarters San Diego, United States
- Employees 80
- Founders John Bell, David Stojdl, Brain Lichty
- Stage Acquired
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Phoneβ’β’β’β’ β’β’β’β’
- Website turnstonebio.com
- Social LinkedIn X
- Acquired by XOMA Corporation (Jun 2025)
- Legal Name Xoma Royalty Corporation
- Total Equity Funding$172.06M (USD)
in 4 rounds
- Latest Funding Round$80M (USD), Series D
Jun 2021
- InvestorsTakeda Pharmaceuticals
& 17 more
- Employee Count80
- Investments & Acquisitions
- Acquired byXOMA Corporation
(Jun 2025)
Products & Services of XOMA Royalty
XOMA Royalty offers a comprehensive portfolio of products and services, including Royalty Acquisition and Royalty Portfolio.
Rights to future royalties are acquired by the company.
A portfolio of royalty licenses is managed strategically.
Funding Insights of XOMA Royalty
XOMA Royalty has successfully raised a total of $172.06M across 4 strategic funding rounds. The most recent funding activity was a Series D round of $80 million completed in June 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $172.06M
- Total Rounds 4
- Last Round Series D β $80M
- First Round $8.56M
(Oct 2015)
- Investors Count 17
All 4 funding rounds of XOMA Royalty with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2021 | $80M | Series D | β | PFM Health Sciences, Point72 | |
| Jan 2019 | $42.1M | Series C | β | β | β |
| Nov 2016 | $41.4M | Series B | β | Orbimed | |
| Oct 2015 | $8.56M | Series A | β | Versant Ventures |
18 investors in total: 18 institutional.
Investors in XOMA Royalty
XOMA Royalty has secured backing from 18 investors, including venture fund and institutional investors. Prominent investors backing the company include Takeda Pharmaceuticals, Northleaf and Citadel.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Healthcare companies are invested in by this private equity firm. | pfmhealthsciences.com | San Francisco, United States | ||
Ridgeback Capital is focused on healthcare and life science investments. | ridgebackcap.com | New York, United States | ||
Venture capital firm managing investments in biotechnology and pharmaceuticals since 1999. | versantventures.com | |||
Venture capital fund focused on tech startups | sixtydegreecapital.com | North York, Canada | ||
Private fund focused on equity, secondary market, fund of funds, and multiple investments | 2009 | northleafcapital.com | Toronto, Canada | |
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
Brace Pharma Capital is focused on investing in innovative therapies. | bracepharma.com | Atlanta, United States | ||
Investments in life sciences, technology, healthtech, and crypto sectors from global locations. | fprimecapital.com | |||
Sectoral Asset Management is focused on global healthcare investment. | 2000 | sectoral.com | Montreal, Canada | |
Diversified investment management is conducted by Teralys Capital. | teralyscapital.com | Montreal, Canada |
Investor details for XOMA Royalty
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of XOMA Royalty
31 people are tracked at XOMA Royalty (12 in leadership, 11 in board & advisors, 8 in team); the tracked headcount is 80.
| Name | Role | Group |
|---|---|---|
John Bell | Co-Founder | Leadership |
David Stojdl | Co-Founder | Leadership |
Brain Lichty | Co-Founder | Leadership |
Sammy Farah | CEO | Leadership |
Catherine Barker | Director | Leadership |
Venkat Ramanan | CFO | Leadership |
Mike Burgess | Interim Chief Medical Officer | Leadership |
Saryah Azmat | Chief Operating Officer | Leadership |
Wendy Worcester | Vice President Finance And Controller | Leadership |
Joseph Campisi | Senior Vice President and General Counsel | Leadership |
Vijay Chiruvolu | Interim Chief Technology Officer | Leadership |
Erica Golding | Vice President, Human Resources | Leadership |
Robert Seder | Scientifc Advisor | Board & advisors |
Patrick Machado | Director | Board & advisors |
Adrian Hill | Scientifc Advisor | Board & advisors |
Alan Melcher | Scientifc Advisor | Board & advisors |
Bernhard Fox | Scientific Advisor | Board & advisors |
Eric Tran | Scientific Advisor | Board & advisors |
Kanya Rajangam | Director | Board & advisors |
Jerel Davis | Chairman | Board & advisors |
11 more people are available in the full profile.
Complete people profiles for XOMA Royalty
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by XOMA Royalty
XOMA Royalty has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Myst Therapeutics.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Developer of cell therapy for treating cancer | myst-tx.com | Los Angeles, United States | 2019 | Jan 2021 | β’β’β’β’ |
Complete acquisition details for XOMA Royalty
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of XOMA Royalty
6 dated milestones of XOMA Royalty across 10 years, from founding to its latest funding, stage changes and deals.
- Founded XOMA Royalty is founded.
- Funding First funding round of $8.6M.
- Acquisition Acquires Myst Therapeutics.
- Funding Latest funding round, Series D, of $80.0M.
- IPO Lists on the stock exchange (IPO).
- Exit Acquired by XOMA Corporation.
Competitors of XOMA Royalty
XOMA Royalty has 3 listed competitors in our database, 3 of them funded. They include Moderna, BridgeBio and BeiGene.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | Therapeutics for genetic diseases are developed through targeted interventions. | ||
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. |
Detailed competitors of XOMA Royalty
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of XOMA Royalty
The website of XOMA Royalty (turnstonebio.com) receives about 1.5K visits a month.
- Monthly visits1.5K
▲ 639.7% vs previous month
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as XOMA Royalty (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Xoma Royalty
Complete news archive for XOMA Royalty
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about XOMA Royalty
XOMA Royalty was founded in 2015.
XOMA Royalty is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Sammy Farah is the CEO of XOMA Royalty, as recorded in our data.
XOMA Royalty is a funded company, having raised a total of $172.06M across 4 funding rounds to date. The company's 1st funding round was a Series A of $8.56M, raised on Oct 2015.
XOMA Royalty has 80 employees.
XOMA Royalty is involved in the aggregation of biotech royalties by acquiring economic rights to future milestone and royalty payments from pre-commercial clinical candidates. The company supports biotech firms with non-dilutive funding to advance drug development. An expansive portfolio of licenses is maintained, covering potential royalty and milestone payments for drug candidates developed by external partners. Operations are focused on mitigating single-asset risks through a diversified portfolio approach within the healthcare and biotechnology sectors.
XOMA Royalty offers Royalty Acquisition and Royalty Portfolio.
XOMA Royalty has made 1 acquisition, including Myst Therapeutics.
XOMA Royalty has 18 investors. Key investors include Takeda Pharmaceuticals, Northleaf, Citadel, Orbimed, and XOMA Corporation.
XOMA Royalty operates through Xoma Royalty Corporation.
Yes. XOMA Royalty was acquired by XOMA Corporation in June 2025.

